
Alzheimer's biomarkers: a blood test for earlier diagnosis
Biomarkers make it possible to detect the brain changes typical of Alzheimer’s disease, even in its early stages. Today they can be measured with a blood test. At NeuroProtect, they are requested and interpreted as part of a full neurological assessment, which is what gives the results their meaning.
What are biomarkers?
In Alzheimer’s disease, two proteins, beta-amyloid and tau, build up in the brain years before symptoms become obvious. Biomarkers are substances that reflect these changes and can be measured in the blood, in the cerebrospinal fluid or with imaging tests such as PET.
The latest blood tests measure specific forms of tau protein, such as p-tau217, and the ratio between different types of amyloid. Used properly, they show with high reliability whether or not a person’s symptoms are due to Alzheimer’s disease, from a simple blood sample.
What we do at NeuroProtect
- Neurology consultation specialising in cognitive decline.
- Neuropsychological assessment to measure memory and other functions objectively.
- Biomarker testing when it is justified.
- Interpretation of the results together with the clinical picture and other tests.
- Treatment and follow-up plan according to the diagnosis.
- Assessment for new treatments in the early stages of the disease.
Book your appointment now
Who is it for?
Biomarker testing is intended for people with symptoms: memory complaints, mild cognitive impairment or early-stage dementia whose cause is unclear. It helps confirm or rule out Alzheimer’s disease and distinguish it from other causes.
It is not routinely recommended for people without any symptoms, because a positive result cannot tell whether or when the disease will appear, and may cause unnecessary worry. That is why it is always requested after a consultation with a neurologist.
Why early diagnosis matters
- Knowing what is happening and planning ahead
- Access to treatments that are only indicated in the early stages
- Ruling out Alzheimer's and looking for other treatable causes
New treatments targeting amyloid protein require its presence to be confirmed before starting, and biomarkers are a key part of that assessment.
What the test involves
It is a normal blood draw, just like any other blood test. No special preparation is needed unless you are told otherwise. The results are discussed in clinic, because they must be interpreted alongside the examination, the neuropsychological assessment and often an MRI scan.
What the result means
A negative result makes it very unlikely that the symptoms are due to Alzheimer’s disease and points the search towards other causes. A positive result, in a person with symptoms, supports the diagnosis and allows treatment options to be considered. In some cases the result is borderline and the assessment is completed with cerebrospinal fluid testing or PET.
You can read more in our article A blood test can help detect Alzheimer’s disease at an early stage and on our Alzheimer’s disease page.
How can patients benefit?
Earlier diagnosis
Greater accuracy
A simple test
Less uncertainty
Access to new treatments
Planning for the future

What to expect at your first visit
- Consultation with a neurologist specialising in cognitive decline.
- Review of your symptoms with the help of a family member.
- Assessment of memory and cognitive function.
- Biomarkers and other tests requested where justified.
- A clear explanation of the results and the plan ahead.
Frequently asked questions
It is not advisable. The result only makes sense as part of a neurological assessment, and routine testing is not recommended for people without symptoms.
In many cases it avoids them. If the result is inconclusive, the neurologist may request further tests.
In a person with symptoms it strongly supports the diagnosis, but it is always interpreted together with the clinical picture and other tests.
It allows you to plan ahead, address risk factors and consider treatments that are only indicated in the early stages.
Book your cognitive decline consultation at NeuroProtect, Estepona.